Although it is established that the major anticancer effects of blockage of the PD-1/PD-L1 pathway are related to enhancing immunity against cancer, there are various reports that PD-L1 triggers intrinsic signaling independent of the immune checkpoint, which promotes tumorigenesis (37, 38). The gene discussed is CD274; the disease is cancer.